ArticleInternational journal of clinical practice2014
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
Article in International journal of clinical practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.The Cochrane database of systematic reviews · 2022Pooled it
- Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.Schizophrenia bulletin · 2016Trial
- Tardive Dyskinesia Induced by Long-Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review.Clinical case reports · 2026Article
- Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.Journal of autism and developmental disorders · 2026Article
- Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Prolonged Tardive Dyskinesia Induced by Long-Acting Paliperidone Palmitate in Schizophrenia: A Case Report.The American journal of case reports · 2026Article
- Sensori- and psychomotor abnormalities, psychopathological symptoms and functionality in schizophrenia-spectrum disorders: a network analytic approach.Schizophrenia (Heidelberg, Germany) · 2025Article
- Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan.Therapeutic advances in psychopharmacology · 2022Review
- Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.Tremor and other hyperkinetic movements (New York, N.Y.) · 2022Review
- Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.Scientific reports · 2018Article
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Current treatment options in psychiatry · 2017Review
- Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.CNS drugs · 2016Review
- Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia.Drug design, development and therapy · 2016Review
- Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.Patient preference and adherence · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the tardive dyskinesia (TD) rate in studies of once-monthly long-acting injectable (LAI) paliperidone palmitate (PP) and once-daily oral paliperidone extended release (Pali ER).
methodsCompleted schizophrenia and bipolar studies for PP and Pali ER (≥ 6 month duration with retrievable patient-level data) were included in this post hoc analysis. Schooler-Kane research criteria were applied using Abnormal Involuntary Movement Scale (AIMS) scores to categorise probable (qualifying AIMS scores persisting for ≥ 3 months) and persistent TD (score persisting ≥ 6 months). Spontaneously reported TD adverse events (AEs) were also summarised. Impact of exposure duration on dyskinesia (defined as AIMS total score ≥ 3) was assessed by summarising the monthly dyskinesia rate.
resultsIn the schizophrenia studies, TD rates for PP (four studies, N = 1689) vs. Pali ER (five studies, N = 2054), were: spontaneously reported AE, 0.18% (PP) vs. 0.10% (Pali ER); probable TD, 0.12% (PP) vs. 0.19% (Pali ER) and persistent TD, 0.12% (PP) vs. 0.05% (Pali ER). In the only bipolar study identified [Pali ER (N = 614)], TD rate was zero (spontaneously reported AE reporting, probable and persistent TD assessments). Dyskinesia rate was higher within the first month of treatment with both PP (13.1%) and Pali ER (11.7%) and steadily decreased over time (months 6-7: PP: 5.4%; Pali ER: 6.4%). Mean exposure: PP, 279.6 days; Pali ER, 187.2 days.
conclusionsRisk of TD with paliperidone was low (< 0.2%), regardless of the formulation (oral or LAI), in this clinical trial dataset. Longer cumulative exposure does not appear to increase the risk of dyskinesias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.